There's now a cure for the deadly genetic disorder known as 'bubble boy' disease

Business Insider | 4/17/2019 | Emma Court
iVchan (Posted by) Level 3
Click For Photo: https://amp.businessinsider.com/images/5cb74b4101428325b455b9e7-2732-1366.jpg

Babies who are born with X-linked severe combined immunodeficiency (XSCID) don't have disease-fighting immune cells. For them, the outside world is an intensely dangerous place.

XSCID was nicknamed "bubble-boy" disease because of a young boy named David Vetter, who famously lived his entire life in a protective plastic bubble. Vetter died more than 30 years ago at age 12 after a failed treatment.

St - Jude - Scientists - Babies - XSCID

St. Jude scientists just announced that they have successfully cured babies with XSCID, using a new experimental gene therapy that targets the disease at the genetic level.

Visit BusinessInsider.com for more stories.

Babies - Condition - Disease - Cold

For babies born with the severe genetic condition known as "bubble-boy" disease, a run-of-the-mill common cold can be deadly.

Born without crucial disease-fighting immune cells, they must be kept isolated from the outside world for their own protection. Those with the disease normally spend months in the hospital and are treated for severe infections. Without treatment, most born with the disease die as infants.

Medicine - Cure - Condition - Researchers - St

A new experimental medicine is now being called a cure for the condition by researchers at St. Jude Children's Research Hospital. Ten babies born with the genetic disease, X-linked severe combined immunodeficiency (XSCID), have been successfully treated, with no apparent side effects, the researchers said on Wednesday.

The kids are now making their own immune cells. Nearly all have been able to go home with their families and live normal lives, including attending day care, with one more recently treated child remaining at St. Jude for the time being.

Patients - XSCID - Dr - Ewelina - Mamcarz

"This is a first for patients with XSCID," said Dr. Ewelina Mamcarz, of the St. Jude Department of Bone Marrow Transplantation and Cellular Therapy. Mamcarz is the first author on a paper about the results, which reports on the first eight children to get the treatment and is being published in the peer-reviewed New England Journal of Medicine.

XSCID, which according...
(Excerpt) Read more at: Business Insider
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!